Takeda Pharmaceutical Company Limited (TAK) Comparison with companies in other sectors?

Takeda Pharmaceutical Company Limited has a share price of 3.16B. You can analyze Takeda Pharmaceutical Company Limited (TAK) competitors across different market sectors through stock heatmaps.

What are TAK's NET and operating margins?

Takeda Pharmaceutical Company Limited (TAK) operating margin is around 0.11, and net profit margin is approximately 0.06 as of the latest reports.

In what way does TAK's earnings per share (EPS) trend reflect its financial momentum?

Takeda Pharmaceutical Company Limited (TAK) EPS is 0.23 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Takeda Pharmaceutical Company Limited is 63.30, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Takeda Pharmaceutical Company Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Takeda Pharmaceutical Company Limited like P/E which is 23.29, P/B which is 0.98, and PEG which is 0.002. Compare them with sector averages to evaluate if the stock is priced fairly.

Takeda Pharmaceutical Company Limited

TAK•NYSE

Healthcare

Drug Manufacturers - Specialty & Generic

$14.55

$0.11(0.76%)

Fundamental Analysis of Takeda Pharmaceutical Company Limited (TAK)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.23

P/E Ratio

63.30

ROE

0.04%

Net Margin

0.06%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$45.98B

Shares OutstandingTotal number of shares issued

$3.16B

Book Value/ShareNet worth per share

$4372.02

Revenue/ShareAnnual revenue per share

$2871.53

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.23

Net MarginNet income as percentage of revenue

6.38%

Operating MarginOperating income as percentage of revenue

11.21%

ROEReturn on shareholders' equity

4.04%

ROAReturn on total assets

1.99%

ROCEReturn on capital employed

4.18%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$321.24

Cash/ShareCash and equivalents per share

$572.41

FCF YieldFree cash flow as percentage of market cap

7.54%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$86.35

Dividend YieldAnnual dividend as percentage of stock price

4.05%

Financial Ratios Analysis data is not available for TAKFinancial Ratios Analysis details for TAK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for TAKSector Benchmarking details for TAK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Takeda Pharmaceutical Company Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Takeda Pharmaceutical Company Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Takeda Pharmaceutical Company Limited's unique business strengths and challenges.

Key Financial Metrics for Takeda Pharmaceutical Company Limited

For Takeda Pharmaceutical Company Limited, essential financial indicators include EPS 0.23, PE 63.30, and ROE 0.04. These key ratios reveal insights into Takeda Pharmaceutical Company Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Takeda Pharmaceutical Company Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Takeda Pharmaceutical Company Limited

Metrics like Net Margin 6.38% and ROA 1.99% shed light on how well Takeda Pharmaceutical Company Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Takeda Pharmaceutical Company Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Takeda Pharmaceutical Company Limited

Using ratios such as P/B Ratio 0.98 and PEG Ratio 0.002, investors can assess whether Takeda Pharmaceutical Company Limited is appropriately valued based on its financials and growth potential. These figures, combined with Takeda Pharmaceutical Company Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Takeda Pharmaceutical Company Limited

Financial health indicators, such as Debt/Equity Ratio 0.73 and Cash Flow $321.24, provide a snapshot of Takeda Pharmaceutical Company Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Takeda Pharmaceutical Company Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Takeda Pharmaceutical Company Limited

Investing in Takeda Pharmaceutical Company Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Takeda Pharmaceutical Company Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;